Compile Data Set for Download or QSAR
Report error Found 9 Enz. Inhib. hit(s) with all data for entry = 12242
Target5-hydroxytryptamine receptor 2B(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  0.190nMAssay Description:Materials and Methods:Receptor Source: Human recombinant 5-HT2B expressed CHO-K1 cellsRadioligand: 1.20 nM [3H] Lysergic acid diethylamide (LSD)Contr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312156(US9604944, 15a (Example 13) | 6-(4-(4-(2-Methoxyph...)
Affinity DataKi:  0.300nMAssay Description:Receptor Source: Human recombinant D2S expressed mammalian cellsRadioligand: [3H]Spiperone (20-60 Ci/mmol) or [3H]-7-hydroxy DPAT, 1.0 nMControl Comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  0.620nMAssay Description:Receptor Source: Human recombinant D2S expressed mammalian cellsRadioligand: [3H]Spiperone (20-60 Ci/mmol) or [3H]-7-hydroxy DPAT, 1.0 nMControl Comp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312156(US9604944, 15a (Example 13) | 6-(4-(4-(2-Methoxyph...)
Affinity DataKi:  0.650nMAssay Description:Materials and Methods:Receptor Source: Human recombinant 5-HT1A expressed mammalian cellsRadioligand: [3H]-8-OH-DPAT (221 Ci/mmol)Control Compound: 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  1.5nMAssay Description:Materials and Methods:Receptor Source: Human recombinant 5-HT1A expressed mammalian cellsRadioligand: [3H]-8-OH-DPAT (221 Ci/mmol)Control Compound: 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  2.5nMAssay Description:Materials and Methods:Receptor Source: Human Cortex or Human recombinant 5-HT2A expressed mammalian cellsRadioligand: [3H]-Ketanserin (60-90 Ci/mmol)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 7(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  2.70nMAssay Description:Materials and Methods: Receptor Source: Human recombinant 5-HT7 expressed CHO cells Radioligand: [3H] Lysergic acid diethylamide (LSD), 4 nM Control ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 6(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312188(US9604944, 15b (Example 14) | 6-(4-(4-(2,3-Dichlor...)
Affinity DataKi:  51nMAssay Description:Materials and Methods:Receptor Source: Human recombinant 5-HT6 expressed mammalian cellsRadioligand: [125I] SB258585, 15 nM or [3H]LSD, 2 nMControl C...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Reviva Pharmaceuticals

US Patent
LigandPNGBDBM312156(US9604944, 15a (Example 13) | 6-(4-(4-(2-Methoxyph...)
Affinity DataKi:  118nMAssay Description:Materials and Methods:Receptor Source: Human Cortex or Human recombinant 5-HT2A expressed mammalian cellsRadioligand: [3H]-Ketanserin (60-90 Ci/mmol)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/21/2024
Entry Details
Go to US Patent